These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 17079309

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.
    Maksaereekul S, Dubie RA, Shen X, Kieu H, Dean GA, Sparger EE.
    Vaccine; 2009 Jun 08; 27(28):3754-65. PubMed ID: 19464559
    [Abstract] [Full Text] [Related]

  • 4. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
    Leutenegger CM, Boretti FS, Mislin CN, Flynn JN, Schroff M, Habel A, Junghans C, Koenig-Merediz SA, Sigrist B, Aubert A, Pedersen NC, Wittig B, Lutz H.
    J Virol; 2000 Nov 08; 74(22):10447-57. PubMed ID: 11044089
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC, Pu R, Pollock D, Vitsky A, Tartaglia J, Paoletti E, Yamamoto JK.
    AIDS; 1998 Jan 01; 12(1):11-8. PubMed ID: 9456250
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
    Kusuhara H, Hohdatsu T, Okumura M, Sato K, Suzuki Y, Motokawa K, Gemma T, Watanabe R, Huang C, Arai S, Koyama H.
    Vet Microbiol; 2005 Jul 01; 108(3-4):155-65. PubMed ID: 15899558
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine.
    Stickney A, Ghosh S, Cave NJ, Dunowska M.
    Vet Microbiol; 2020 Nov 01; 250():108865. PubMed ID: 33045631
    [Abstract] [Full Text] [Related]

  • 18. Experimental vaccine protection against feline immunodeficiency virus.
    Yamamoto JK, Okuda T, Ackley CD, Louie H, Pembroke E, Zochlinski H, Munn RJ, Gardner MB.
    AIDS Res Hum Retroviruses; 1991 Nov 01; 7(11):911-22. PubMed ID: 1662057
    [Abstract] [Full Text] [Related]

  • 19. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN, Beatty JA, Cannon CA, Stephens EB, Hosie MJ, Neil JC, Jarrett O.
    AIDS Res Hum Retroviruses; 1995 Sep 01; 11(9):1107-13. PubMed ID: 8554908
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.